Novel antifungal agents: a patent review (2011 – present)

Bibliography

• Pfaller M, Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med 2012;4:165rv13
   PubMed Web of Science ®Google Scholar
• Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010;18:195-204
   PubMed Web of Science ®Google Scholar
• Weitzman I, Summerbell R. The dermatophytes. Clin Microbiol Rev 1995;8:240-59
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003;53:243-58
   PubMed Web of Science ®Google Scholar
• Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14(Suppl s4):5-24
   PubMedGoogle Scholar
• Tampieri MP. Update on the diagnosis of dermatomycosis. Parassitologia 2004;46:183-6
   PubMedGoogle Scholar
• Odds F. Antifungal agents: their diversity and increasing sophistication. Mycologist 2003;17:51-5
   Google Scholar
• Ruiz-Camps I, Cuenca-Estrella M. Antifúngicos para uso sistémico. Enferm Infecc Microbiol Clin 2009;27:353-62
   PubMedGoogle Scholar
• Mathew BP, Nath M. Recent approaches to antifungal therapy for invasive mycosis. ChemMedChem 2009;4:310-23
   PubMedGoogle Scholar
• Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoamer Micol 2008;25:101-6
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010;9:719-27
   PubMed Web of Science ®Google Scholar
• Sheng C, Zhang W. New lead structures in antifungal drug discovery. Curr Med Chem 2011;18:733-66
   PubMed Web of Science ®Google Scholar
• Calugi Ch, Trabocchi A, Guarna A. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010). Expert Opin Ther Patents 2011;21:381-97
   PubMed Web of Science ®Google Scholar
• Offner F, Krcmery V, Boogaerts M, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother 2004;48:4808-12
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med 2012;125:S25-38
   PubMed Web of Science ®Google Scholar
• Baginski M, Czub J. Amphotericin B and its new derivatives–mode of action. Curr Drug Metab 2009;10:459-69
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother 2011;66:457-65
   PubMed Web of Science ®Google Scholar
• Onyewu C, Blankenship J, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata and Candida krusei. Antimicrob Agents Chemother 2003;47:956-64
   PubMed Web of Science ®Google Scholar
• European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/07/WC500146613.pdf [Last accessed 26 September 2013]
   Google Scholar
• García Rodríguez L, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann P, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 2005;366:1435-42
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Lorus Therapeutic, Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents. US7884120; 2011
   Google Scholar
• Lorus Therapeutic, Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents. US8394815; 2013
   Google Scholar
• Daewoong Pharmaceutical Co. Antifungal triazole derivatives. US7968579; 2011
   Google Scholar
• Daewoong Pharmaceutical Co. Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same. US8063229; 2011
   Google Scholar
• Mitsubishi Chemical Corp. Indazole compounds and the use thereof. US5705453; 1998
   Google Scholar
• Syngenta Ltd. Pesticidal indazole or benzotriazole derivatives. EP1171437; 2003
   Google Scholar
• Council of Scientific & Industrial Research and FDC Ltd. Antifungal compounds containing benzothiazinone, benzoxazinone, or benzoxazolinone and process thereof. US8129369; 2012
   Google Scholar
• Council of Scientific & Industrial Research and FDC Ltd. Thiophene containing analogues of fluconazole as antifungal agents and process for their preparation. US8236840; 2012
   Google Scholar
• Council of Scientific & Industrial Research and FDC Ltd. Thiophene containing analogues of fluconazole as antifungal agents and process thereof. EP2346861; 2013
   Google Scholar
• Barrier Therapeutics, Inc. Modified azole compounds as antifungal and antibacterial agents. US8147852; 2012
   Google Scholar
• Andriole V. Current and future antifungal therapy: new targets for antifungal therapy. Intern J Antimicrob Agents 2000;16:317-21
   PubMed Web of Science ®Google Scholar
• Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother 2012;13:1131-42
   PubMed Web of Science ®Google Scholar
• Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays 2006;28:799-808
   PubMed Web of Science ®Google Scholar
• Latgé JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol 2007;66:279-90
   PubMed Web of Science ®Google Scholar
• Latgé JP. Tasting the fungal cell wall. Cell Microbiol 2010;12:863-72
   PubMed Web of Science ®Google Scholar
• Kapteyn JC, Van Den Ende H, Klis FM. The contribution of cell wall proteins to the organization of the yeast cell wall. Biochim Biophys Acta 1999;426:373-83
   Google Scholar
• Bernard M, Latgé JP. Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 2001;39(Suppl 1):9-17
   PubMed Web of Science ®Google Scholar
• Klis FM, De Groot P, Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Med Mycol 2001;39(Suppl 1):1-8
   PubMed Web of Science ®Google Scholar
• Grun CH, Hochstenbach F, Humbel BM, et al. The structure of cell wall alpha-glucan from fission yeast. Glycobiology 2005;15:245-57
   PubMed Web of Science ®Google Scholar
• Molano J, Blowers B, Cabib E. Distribution of chitin in the yeast cell wall. J Cell Biol 1980;85:199-212
   PubMed Web of Science ®Google Scholar
• Valdivieso H, Durán A, Roncero C. Chitin synthases in yeast and fungi. EXS 1999;87:55-69
   PubMedGoogle Scholar
• Cabib E, Schmidt M. Chitin synthase III activity, but not the chitin ring, is required for remedial septa formation in budding yeast. FEMS Microbiol Lett 2003;224:299-305
   PubMedGoogle Scholar
• Lenardon MD, Munro CA, Gow NA. Chitin synthesis and fungal pathogenesis. Curr Opin Microbiol 2010;13:416-23
   PubMed Web of Science ®Google Scholar
• Ruiz-Herrera J, Xoconostle-Cazares B. Molecular and genetic control of chitin biosynthesis in fungi. Arch Med Res 1995;26:315-21
   PubMedGoogle Scholar
• Ruiz-Herrera J, San-Blas G. Chitin synthesis as target for antifungal drugs. Curr Drug Targets Infect Disord 2003;3:77-91
   PubMedGoogle Scholar
• Chaudhary PM, Tupe SG, Deshpande MV. Chitin synthase inhibitors as antifungal agents. Mini Rev Med Chem 2013;13:222-36
   PubMed Web of Science ®Google Scholar
• Selvaggini S, Munro CA, Paschoud S, et al. Independent regulation of chitin synthase and chitinase activity in Candida albicans and Saccharomyces cerevisiae. Microbiol 2004;150:921-8
   PubMedGoogle Scholar
• Kuranda MJ, Robbins PW. Chitinase is required for cell separation during growth of Saccharomyces cerevisiae. J Biol Chem 1991;266:19758-67
   PubMed Web of Science ®Google Scholar
• Takaya N, Yamazaki D, Horiuchi H, et al. Cloning and characterization of a chitinase-encoding gene (chiA) from Aspergillus nidulans, disruption of which decreases germination frequency and hyphal growth. Biosci Biotechnol Biochem 1998;62:60-5
   PubMed Web of Science ®Google Scholar
• Klis FM, Mol P, Hellingwerf K, Brul S. Dynamics of cell wall structure in Saccharomyces cerevisiae. FEMS Microbiol Rev 2002;26:239-56
   PubMed Web of Science ®Google Scholar
• Poulain D, Jouault T. Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr Opin Microbiol 2004;7:342-9
   PubMed Web of Science ®Google Scholar
• Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008;47:6991-7000
   PubMed Web of Science ®Google Scholar
• Tsai YH, Liu X, Seeberger PH. Chemical biology of glycosylphosphatidylinositol anchors. Angew Chem Int Ed Engl 2012;51(46):11438-56
   PubMed Web of Science ®Google Scholar
• Pittet M, Conzelmann A. Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 2007;1771:405-20
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009;43:1647-57
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Sheehan D, Puzniak L, et al. Echinocandins: are they all the same? J Chemother 2011;23:319-25
   PubMed Web of Science ®Google Scholar
• Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000;4:368-77
   Google Scholar
• Ripeau JS, Aumont F, Belhumeur P, et al. Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother 2002;46:3096-100
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-22
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3:71-97
   PubMedGoogle Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41
   PubMed Web of Science ®Google Scholar
• Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001;39(Suppl 1):55-66
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006;19:763-87
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51
   PubMed Web of Science ®Google Scholar
• Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin 2013;29(Suppl 4):13-18
   PubMedGoogle Scholar
• Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006;4:325-42
   PubMedGoogle Scholar
• Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005;27:657-73
   PubMed Web of Science ®Google Scholar
• Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999;43:1401-5
   PubMed Web of Science ®Google Scholar
• Milewski S, Mignini F, Borowski E. Synergistic action of nikkomycin X/Z with azole antifungals on Candida albicans. J Gen Microbiol 1991;137:2155-61
   PubMedGoogle Scholar
• Tariq VN, Scott EM, McCain NE. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob Agents Chemother 1995;39:2615-19
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis, Inc. Antifungal agents. US7863465; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis, Inc. Antifungal agents. CN101454010; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis, Inc. Antifungal agents. EP2007396; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis, Inc. Antifungal agents. US8188085; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis, Inc. Antifungal agents. US8222255; 2012
   Google Scholar
• Peláez F, Cabello A, Platas G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species. Biological activity and taxonomy of the producing organism. Syst Appl Microbiol 2000;23:333-43
   PubMed Web of Science ®Google Scholar
• Heasley BH, Pacofsky GH, Mamai A, et al. Synthesis and biologically active derivatives of enfumafungin as orally bioavailable inhibitors of beta-1,3-glucan synthase. Bioorg Med Chem Lett 2012;22:6811-16
   PubMed Web of Science ®Google Scholar
• Korea Research Institute of Bioscience and Biotechnology. Berberrubine derivatives having antifungal activities. US7915276; 2011
   Google Scholar
• Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2:94-103
   Google Scholar
• Park K, Kang K, Kim K, et al. HWY-289, a novel semi-synthetic protoberberine derivative with multiple target sites in Candida albicans. J Antimicrob Chemother 2001;47:513-19
   PubMedGoogle Scholar
• University Court of the University of Dundee. Inhibitor compounds. US 8207175; 2012
   Google Scholar
• Chu H. Investigation of family 18 chitinases and inhibitors by computer-aided approaches. Curr Drug Targets 2012;13:502-11
   PubMedGoogle Scholar
• Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006;7:653-63
   PubMed Web of Science ®Google Scholar
• Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010;135:1-11
   PubMed Web of Science ®Google Scholar
• Phermonicin Biotech. Antifungal bifunctional molecules, methods of construction and methods of treating fungal infection therewith. US7915382; 2011
   Google Scholar
• C3 Jian, Inc. Antibacterial and antifungal peptides. US 8303962; 2012
   Google Scholar
• MCS Lab. Esters of 2-phenylalkanenitriles and antifungal compositions containing them. US 8153688; 2012
   Google Scholar
• MCS Lab. Esters of 2-phenylalkanenitriles and antifungal compositions containing them. EP 2148854; 2013
   Google Scholar
• Im D, Cheong C, Lee S. Lipase-catalyzed remote kinetic resolution of arylic nitrites with adjacent quaternary chiral center and the determination of their absolute configuration. J Mol Catal B Enzym 2003;26:131-43
   Google Scholar
• Anacor Pharmaceuticals, Inc. Boron-containing small molecules. US8039451; 2011
   Google Scholar
• Anacor Pharmaceuticals, Inc. Boron-containing small molecules. US8440642; 2013
   Google Scholar
• Anacor Pharmaceuticals, Inc. Halogen-substituted boronophtalides for the treatment of infections. EP1853251; 2013
   Google Scholar
• Eisal R&D Management Co. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same. EP2065377; 2011
   Google Scholar
• Eisal R&D Management Co. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same. US8183264; 2012
   Google Scholar
• Eisal R&D Management Co. Pyridine derivatives substituted with heterocyclic ring and gamma-glutamyl amino group and antifungal agents contaning the same. US8188119; 2012
   Google Scholar
• Universita degli Studi de Siena. Cyclic guanidine derivatives and uses thereof. EP2274290; 2012
   Google Scholar
• Florida Agricultural and Mechanical University, Tallahassee, Fl (USA). 3-Substituted quinolinium and 7H-indolo[2,3-c]quinolinium salts as new anti-infectives. US8288410; 2012
   Google Scholar